Stay updated with breaking news from Data Presented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Leal Health ("Leal" or "the Company"), formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes...
Vaccitech, a biopharmaceutical company, has created a vaccine named VTP-300. They are currently showcasing positive initial results through a poster presentation at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated ... | April 17, 2023
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the...
– Data showcase the potential of glofitamab and mosunetuzumab to address diverse patient needs – – Data presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab, given as a fixed course, induced early and durable responses in people with heavily pretreated large B-cell lymphoma – – 27-month follow-up data showed mosunetuzumab continued to induce high and durable responses in people with relapsed or refractory follicular lymphoma, with 60% experiencing a complete response –